Richard E. Gilbert

MD, FRCPC, FRACP, FACP, FASN, PhD

Scientist, Keenan Research Centre for Biomedical Science

Biography

Richard Gilbert is Professor of Medicine at the University of Toronto, Canada Research Chair in Diabetes Complications and Head of the Division of Endocrinology at St. Michael’s Hospital in Toronto. His major interests are in the treatment and prevention of diabetic complications with an emphasis on nephropathy and heart failure. Dr. Gilbert has published over 220 peer-reviewed manuscripts, has numerous patents and co-founded Fibrotech, a biotechnology company that has brought novel anti-fibrotic therapies from the bench to early phase human trials. He is currently a member of the editorial board of Diabetes. Current research projects relate to the use of new therapies for the prevention and treatment of chronic kidney disease and heart failure. In addition to his bench research, Dr. Gilbert is actively involved in teaching and knowledge translation. He currently heads Guidelines Committees for the management of hypertension in diabetes.

Recent Publications

  1. Zhang, Y, Thai, K, Kepecs, DM, Winer, D, Gilbert, RE. Reversing CXCL10 Deficiency Ameliorates Kidney Disease in Diabetic Mice. Am. J. Pathol. 2018; :. doi: 10.1016/j.ajpath.2018.08.017. PubMed PMID:30273603 .
  2. Zhang, Y, Thai, K, Jin, T, Woo, M, Gilbert, RE. SIRT1 activation attenuates α cell hyperplasia, hyperglucagonaemia and hyperglycaemia in STZ-diabetic mice. Sci Rep. 2018;8 (1):13972. doi: 10.1038/s41598-018-32351-z. PubMed PMID:30228292 PubMed Central PMC6143559.
  3. Connelly, KA, Zhang, Y, Desjardins, JF, Thai, K, Gilbert, RE. Dual inhibition of sodium-glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction. Cardiovasc Diabetol. 2018;17 (1):99. doi: 10.1186/s12933-018-0741-9. PubMed PMID:29981571 PubMed Central PMC6035399.
  4. Bugyei-Twum, A, Ford, C, Civitarese, R, Seegobin, J, Advani, SL, Desjardins, JF et al.. Sirtuin 1 activation attenuates cardiac fibrosis in a rodent pressure overload model by modifying Smad2/3 transactivation. Cardiovasc. Res. 2018;114 (12):1629-1641. doi: 10.1093/cvr/cvy131. PubMed PMID:29800064 PubMed Central PMC6148332.
  5. Nerenberg, KA, Zarnke, KB, Leung, AA, Dasgupta, K, Butalia, S, McBrien, K et al.. Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Can J Cardiol. 2018;34 (5):506-525. doi: 10.1016/j.cjca.2018.02.022. PubMed PMID:29731013 .
  6. Levin, A, Adams, E, Barrett, BJ, Beanlands, H, Burns, KD, Chiu, HH et al.. Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease (Can-SOLVE CKD): Form and Function. Can J Kidney Health Dis. 2018;5 :2054358117749530. doi: 10.1177/2054358117749530. PubMed PMID:29372064 PubMed Central PMC5774731.
  7. Gerstein, HC, Jung, H, Rydén, L, Diaz, R, Gilbert, RE, Yusuf, S et al.. Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention). Circulation. 2018;137 (1):88-90. doi: 10.1161/CIRCULATIONAHA.117.030924. PubMed PMID:29279340 .
  8. Papademetriou, V, Nylen, ES, Doumas, M, Probstfield, J, Mann, JFE, Gilbert, RE et al.. Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study. Am. J. Med. 2017;130 (12):1465.e27-1465.e39. doi: 10.1016/j.amjmed.2017.05.047. PubMed PMID:28842165 .
  9. Leung, AA, Daskalopoulou, SS, Dasgupta, K, McBrien, K, Butalia, S, Zarnke, KB et al.. Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. Can J Cardiol. 2017;33 (5):557-576. doi: 10.1016/j.cjca.2017.03.005. PubMed PMID:28449828 .
  10. Gilbert, RE. Proximal Tubulopathy: Prime Mover and Key Therapeutic Target in Diabetic Kidney Disease. Diabetes. 2017;66 (4):791-800. doi: 10.2337/db16-0796. PubMed PMID:28325740 .
Search PubMed

Affiliations & Other Activities

  • Staff Physician, Department of Medicine, Division of Endocrinology, St. Michael’s Hospital
  • Professor, Department of Medicine, University of Toronto
X